Elliott Sigal, MD, PhD
Elliott Sigal, M.D., PhD is a former Executive Vice President and Director of Bristol-Myers Squibb. He served as Chief Scientific Officer and President of R&D for Bristol-Myers Squibb from 2004 until 2013. Under his leadership, fourteen new medicines came to market including Baraclude (Hepatitis B), Orencia (Rheumatoid Arthritis), Sprycel (Leukemia), Eliquis (Stroke), and Yervoy (Melanoma). He built BMS research into a lead position in immuno-oncology which is revolutionizing the practice of medicine in cancer. In 2012, Dr. Sigal was named the best R and D chief in the pharmaceutical industry by Scrip Intelligence.
Dr. Sigal was a principal architect of the successful Biopharma Transformation Strategy of the company and was instrumental in increasing R&D productivity, developing the company’s strategy in biologics and acquiring external innovation in Bristol’s String of Pearls initiative.
Dr. Sigal currently serves as a senior advisor to the healthcare team of New Enterprise Associates and also consults for select biotechnology companies including Amgen. He is a member of the Board of Directors for Adaptimmune, Spark Therapeutics and the Mead Johnson Nutrition Company and serves on the Scientific Advisory Board for Surface Oncology. Dr. Sigal received his M.D. from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco (UCSF). Prior to medical school he received a B.S., M.S., and Ph.D. in industrial engineering from Purdue University.